An upcoming second-line SCLC phase 3 will include Imdelltra as a control option.
ApexOnco Front Page
Recent articles
The FDA has cleared GSK’s drug again, after a no from the advisory committee.
New trial starts include MediLink's 12th clinical-stage Tmalin candidate.
After trimming its cell therapy pipeline last year, the group is now out entirely.
The Titan CD8-guiding technology seems to have spawned a new variant.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
A single-arm trial was enough for J&J’s Inlexzo nod.
